CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorNeuralink Corp

About this trial

The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia). The N1 Implant is a small, wireless device placed in the skull. It connects to tiny threads inserted into the brain by the R1 Robot, which is a machine designed to carefully place these threads. This study will help researchers learn how well the implant and robot work and if they are safe for use.

Eligibility criteria

Qualifiers

Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below

Life expectancy ≥ 12 months.

Ability to communicate in English

Presence of a stable caregiver

Disqualifiers

Moderate to high risk for serious perioperative adverse events

Active implanted devices

Morbid obesity (Body Mass Index > 40)

History of poorly controlled seizures or epilepsy

Trial design

Treatments tested in this trial

  • N1 Implant
  • R1 Robot

Treatment groups

6 Participants
are divided into 1 treatment group

Sponsors and collaborators

Neuralink Corp

Lead sponsor

University Health Network, Toronto

Collaborator